Quantcast

Latest DNA vaccination Stories

2011-07-05 03:00:00

BLUE BELL, Pa., July 5, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that novel data from a preclinical study of its SynCon(TM) DNA vaccine against HIV were published in two separate scientific journals. In vaccinated animals, the studies demonstrated Inovio's HIV vaccine's ability to harness the power of the immune system, generating unique...

2011-07-01 03:00:00

BLUE BELL, Pa., July 1, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Dr. Avtar Dhillon has become non-executive Chairman of the Board of Directors. Dr. Dhillon was initially appointed as Executive Chairman of the Board in 2009 in conjunction with the merger between Inovio Biomedical and VGX Pharmaceuticals with a mandate to provide...

2011-06-30 03:00:00

BLUE BELL, Pa., June 30, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved compelling immune responses in a study of its multi-subtype DNA vaccine for foot-and-mouth (FMD) disease administered by Inovio's proprietary vaccine delivery technology in sheep, the second large animal in which this vaccine was evaluated. Strong...

2011-06-29 03:00:00

BLUE BELL, Pa., June 29, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its therapeutic DNA vaccine for prostate cancer showed remarkable immune responses in monkeys, following similarly strong, antigen-specific and sustainable T cell levels in previously reported data from earlier animal studies. The data was presented by Dr. J. Joseph...

2011-06-17 03:00:00

BLUE BELL, Pa., June 17, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that its subsidiary VGX Animal Health, Inc., a developer of DNA-based vaccines and therapies for companion and food animals, has achieved strong T cell responses from VAH-5000D, its DNA vaccine encoding telomerase reverse transcriptase (TERT) for the treatment of dogs with cancer. This preclinical data was presented by Dr. Douglas Kern, DVM, VGX Animal Health's Vice President of...

2011-06-15 03:00:00

BLUE BELL, Pa., June 15, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company will make presentations at three conferences: 2nd World Cancer Vaccines SummitBoston, MA, June 22-23Radisson Boston Inovio PresentationMark Bagarazzi, MD, Chief Medical Officer"Advancing Cancer Vaccines Through in vivo Electroporation"June 22, 2011 2:30 pm...

2011-06-09 03:00:00

BLUE BELL, Pa., June 9, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its majority-owned subsidiary, VGX Animal Health, Inc, will present at VetHealth Global 2011, an international animal health and nutrition business conference being held June 14-17, 2011, in Charlottetown, Prince Edward Island, Canada. Douglas Kern, DVM, VGX Animal...

2011-06-08 06:00:00

ATLANTA, June 8, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX) announced today the publication of the results of preclinical testing of a simian prototype of its 2nd generation HIV/AIDS vaccine. The article, titled "Prevention of Infection by a Granulocyte-Macrophage Colony-Stimulating Factor Co-Expressing DNA/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine," will appear in the July 1 issue of The Journal of Infectious Diseases. A PDF of the article can be...

2011-05-26 05:01:00

SAN DIEGO, May 26, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today it will initiate three Phase II clinical trials to assess its cancer-destroying, tissue-sparing ElectroImmunotherapy technology in patients with melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. (Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO) OncoSec's lead...

2011-05-17 03:00:00

BLUE BELL, Pa., May 17, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company will highlight its DNA vaccines and electroporation delivery technology at the 14th Annual Meeting of the American Society of Gene & Cell Therapy to be held May 18-21 in Seattle, Washington at the Washington State Convention & Trade Center. Several of...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin